InflaRx price target raised to $10 from $7 at Guggenheim

Guggenheim raised the firm’s price target on InflaRx (IFRX) to $10 from $7 and keeps a Buy rating on the shares. All programs remain on track following the Q4, notes the analyst, who is “encouraged” by the updates from both vilobelimab and INF904. Once the company reports interim data for both ongoing programs, investors should “begin to realize the significant opportunity for the company,” the analyst argues.